S producer of a safe supply of the blood thinnerHeparin Today Dr

Philadelphia-based ITA Partners delivers transformational services for cancerand advanced renal disease patientsPHILADELPHIA(Business Wire)ITA Partners, Inc. Currently specializing in oncology and end-stage renal disease, ITA improvesmedical outcomes for patients and thus delivers quantifiable cost savings forthem and for payers. "ITA Partners delivers transformational services, filling voids that diminishquality and exacerbate costs of American health care," said Dr. Soon-Shiong."ITA's information technology and disease-specific, expert doctors and nurseshave a ground-breaking model that collaboratively joins patients, physicians andpayers in the push for quality care. ITA fulfills a vision for me, ensuring thattreatment in two of the most costly and deadly diseases is accurately prescribedand followed, side effects are well-managed, and patients have the personalizedsupport they need to receive unbiased, evidence-based information and beempowered to participate in the decision-making process of their health." ITA Chairman Robert L. Comis, MD, also is president and chairman of theCoalition of Cancer Cooperative Groups.

The Coalition represents the NationalCancer Institute-supported cooperative groups that enroll nearly half of allU.S patients participating in cancer clinical trials Dr Comis has worked withDr. Soon-Shiong on several initiatives to promote quality care as a key driverof healthcare reform "Dr. "Heis truly a visionary leader." In addition to his many accomplishments as a physician and surgeon, Dr.Soon-Shiong performed the first islet-cell transplant, is the developer of thefirst cancer-fighting drug engineered through nanotechnology, and is the namedinventor on more than 50 patents. An Illinois pharmaceutical company he startedis the sole remaining U.S producer of a safe supply of the blood thinnerHeparin Today, Dr. Soon-Shiongs efforts are turned more intensively onto thewidening gap between the rapid advancements in medicine and the physicianscognitive abilities to process and interpret such huge amounts of information atsuch a rapid pace.

As Chairman of the newly formed Chan Soon-Shiong Family Foundation, he and hisfamily are focusing on charitable endeavors that will improve health care inAmerica and the welfare of its patients. Soon-Shiong is on the health advisory board and thePresident's Council of RAND. At RAND, he supported the development of theComprehensive Assessment of Reform Efforts (COMPARE), recently released by theRAND Corporation. ITA President and CEO Eduardo Beruff said the company welcomes Dr. "Payers, patients and physicians value ITA's ability to validate that treatmentprotocols for patients with cancer and renal failure meet national guidelinesand to provide collaborative, personalized support," Mr Beruff said "We aredelighted to have Dr. Soon-Shiongs wisdom, leadership and energy as we workaggressively to advance the age of e-medicine, during the year in whichtransformational change in health care is imminent." Mr. Beruff cites several statistics demonstrating the need for ITA: 15 ofcancer diagnoses are incorrect, more than 25 of prescribed treatment plansdeviate from proven guidelines, and 45 of patients do not comply with orcomplete treatment.